• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
74,130.24 810.69
( 1.11%)
Global Indices
Nasdaq
46,525.67 -61.07
(-0.13%)
Dow Jones
6,603.69 7.37
(0.11%)
Hang Seng
53,576.26 452.77
(0.85%)
Nikkei 225
10,436.29 71.50
(0.69%)
Forex
USD-INR
93.02 -0.15
(-0.16%)
EUR-INR
107.32 -0.65
(-0.60%)
GBP-INR
123.03 -0.78
(-0.63%)
JPY-INR
0.58 0.00
(-0.67%)

EQUITY - MARKET SCREENER

Mahanagar Telephone Nigam Ltd
Industry :  Telecommunications - Service Provider
BSE Code
ISIN Demat
Book Value()
500108
INE153A01019
-457.3346032
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MTNL
0
1540.98
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

vipul ltd
Alembic Pharma slumps after receiving two USFDA observations for karakhadi facility
Feb 19,2026
The inspection was conducted from 9th February to 18th February 2026. At the end of the inspection, a ‘Form 483’ was issued with 2 observations and the company said that it will respond to the US FDA within the stipulated timelines.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

The company’s consolidated net profit fell 3.9% to Rs 132.97 crore despite a 10.8% jump in net sales to Rs 1,876.31 crore in Q3 FY26 over Q3 FY25.